In light of the research gap on OUD outcomes among patients taking both buprenorphine and benzodiazepines, our study used the IBM® MarketScan® databases (2006–2016) to: (1) quantify odds of non-fatal drug-related poisoning (including overdoses) associated with benzodiazepine use in OUD patients; (2) determine if BZD use improves, nullifies, or reverses the protective effect of buprenorphine in OUD patients; (3) evaluate if different sedative/hypnotic subtypes (e.g., long-acting vs short-acting agents, Z drugs) correspond to different poisoning risk.
